Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Intangibles (2016 - 2026)

Cumberland Pharmaceuticals' Intangibles history spans 16 years, with the latest figure at $14.0 million for Q4 2025.

  • On a quarterly basis, Intangibles fell 21.95% to $14.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.0 million, a 21.95% decrease, with the full-year FY2025 number at $14.0 million, down 21.95% from a year prior.
  • Intangibles hit $14.0 million in Q4 2025 for Cumberland Pharmaceuticals, down from $15.0 million in the prior quarter.
  • Over the last five years, Intangibles for CPIX hit a ceiling of $34.5 million in Q1 2022 and a floor of $14.0 million in Q4 2025.
  • Historically, Intangibles has averaged $23.9 million across 5 years, with a median of $24.4 million in 2021.
  • Biggest five-year swings in Intangibles: increased 27.7% in 2022 and later fell 28.41% in 2024.
  • Tracing CPIX's Intangibles over 5 years: stood at $24.0 million in 2021, then increased by 27.7% to $30.6 million in 2022, then decreased by 26.1% to $22.6 million in 2023, then fell by 20.5% to $18.0 million in 2024, then fell by 21.95% to $14.0 million in 2025.
  • Business Quant data shows Intangibles for CPIX at $14.0 million in Q4 2025, $15.0 million in Q3 2025, and $16.0 million in Q2 2025.